10:44 AM EDT, 06/10/2026 (MT Newswires) -- Optimi Health ( OPTH ) announced Wednesday the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial.

The shipment includes psilocybin biomass and finished 5mg psilocybin capsules, supplied to support a planned Phase 2 clinical trial in the United Kingdom, added the company.

"The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression (TRD)," said the company.

Optimi plans to announce the trial partner and indication at a later date.

The exported product was manufactured at Optimi's GMP facility in Princeton, British Columbia, Canada, and shipped under export authorization issued by Health Canada and import authorization from the UK Home Office, stated the company.

Shares of the company were last seen down $0.05 at $6.70 on the Canadian Securities Exchange.

Price: 6.70, Change: -0.05, Percent Change: -0.74